WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999040945) COMBINATION OF A NUCLEIC ACID AND A VASOACTIVE AGENT FOR ENHANCED GENE DELIVERY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/040945    International Application No.:    PCT/US1999/002702
Publication Date: 19.08.1999 International Filing Date: 09.02.1999
Chapter 2 Demand Filed:    06.09.1999    
IPC:
A61K 48/00 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 5th floor, 1111 Franklin Street Oakland, CA 94607 (US) (For All Designated States Except US).
HAMMOND, H., Kirk [US/US]; (US) (For US Only)
Inventors: HAMMOND, H., Kirk; (US)
Agent: POLIZZI, Catherine, M.; Morrison & Foerster LLP 755 Page Mill Road Palo Alto, CA 94304-1018 (US).
GOLDIN, Douglas, Michael; J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5LX (US)
Priority Data:
09/021,773 11.02.1998 US
Title (EN) COMBINATION OF A NUCLEIC ACID AND A VASOACTIVE AGENT FOR ENHANCED GENE DELIVERY
(FR) TRAITEMENT DE L'ANGIOGENESE PAR TRANSFERT DE GENES ET TECHNIQUES D'APPORT INTRAVASCULAIRE DE GENES
Abstract: front page image
(EN)Transgene-inserted vectors are effectively used for $i(in vivo) gene therapy for peripheral vascular disease, heart disease and other conditions, by direct injection of the vector into arteries supplying the tissue to be targeted, preferably in combination with a vasoactive agent that is infused into the artery prior to or coincident with delivery of the vector.
(FR)Dans la thérapie génique $i(in vivo) des troubles vasculaires périphériques, des maladies cardiaques et autres pathologies, on obtient de bons résultats avec des vecteurs dans lesquels sont insérés des transgènes. Pour cela, on injecte directement le vecteur dans les artères qui vascularisent le tissu cible, en l'associant de préférence à un agent vasoactif que l'on perfuse dans l'artère. La perfusion d'agent vasoactif se fait avant ou en même temps que l'apport de vecteur.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)